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Tuberculosis is one of the most ancient human pathogens. Very early in the 
history of humans, tuberculosis spread throughout the world and currently infects one 
third of the world’s population
1
. Tuberculosis, both as a pathogen and a disease state, is 
fascinating in its own right. Considering the global public health significance of 
tuberculosis, which infects one third of the world’s population and kills over 1.5 million 
people per year, tuberculosis remains a threat and demands further research. For these 
reasons, my undergraduate research has largely centered on tuberculosis. Chapter 1 gives 
a broad overview of tuberculosis, applicable but not specific to my research. Each 
subsequent chapter focuses on a research project, with relevant additional background on 
tuberculosis. Chapter 2 is based on an internship at the Texas Department of State Health 
Services analyzing reasons for delayed completion of tuberculosis therapy for patients 
whose therapy initiated in Texas in 2006. Chapter 3 examines the potential for molecular 
methods of tuberculosis in low-resource setting, building off of my experience using 
mutations in the rpoB gene as a surrogate marker of rifampin resistance in Afghanistan. 
Chapter 4 briefly expands upon further work done in the lab of Dr. Andrew Ellington at 
the University of Texas at Austin under the supervision of Xi Chen, developing non-





I. Introduction to Tuberculosis 
Historical Context 
Tuberculosis is an ancient pathogen. Documents by Hippocrates and Galen 
describe symptoms of tuberculosis
2
. As well, archaeological data show bodies with signs 
of tuberculosis. With industrialization and increased population density during the 
eighteenth and nineteenth centuries, tuberculosis created a significant health burden, 
known as consumption and the white plague. During this period of time, tuberculosis 
caused one in seven deaths in Europe
3
. Efforts to cure and contain the disease, such as 
bleeding, were based on a limited and often mistaken understanding of the etiology of 
tuberculosis, and usually did more harm than good. The failure to control tuberculosis 
partially stemmed from the fact that though the infectiousness of tuberculosis was posited 
as early as 1790, much of Northern Europe continued to discount the possibility of 
tuberculosis infectiousness  and no precautions against transmission were taken. Because 
tuberculosis often affected multiple members of the same family, tuberculosis was 
sometimes considered hereditary.  
The body of evidence for a microbial basis for tuberculosis continued to grow 
over the nineteenth century, culminating in 1882 with the isolation of Micobacterium 
tuberculosis by Robert Koch. Koch was also first to discover and promote the tuberculin 
skin test as an accurate diagnostic for asymptomatic tuberculosis, a test that continues to 
be used to this day
2
. Dr. Herman Biggs pioneered a public health approach to 
tuberculosis, in view of its contagious nature. As early as 1889, he convinced New York 
City to require all health providers to report cases of tuberculosis to the city health 
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officials. To this day, tuberculosis is monitored, managed, and fought by many level of 
public health agencies, from a city health department all the way to the WHO
2,53
.  
Mortality and prevalence due to tuberculosis dropped dramatically in the time 
between Koch and the nineteen fifties, when the first real cure appeared- streptomycin. 
For a time, the only challenge presented by tuberculosis treatment was getting the 
medicine to all those who needed it. However, strains resistant to antibiotics quickly rose 
in the bacteria population. The rise of HIV, with its deadly synergy with tuberculosis, 
slowed and sometimes reversed the steady decline in tuberculosis incidence observed for 
the past 150 years. Today, tuberculosis remains a global pandemic, with the added danger 
of MDR, multiple drug resistant, and XDR- extremely drug resistant strains. The public 
health approach which drove the substantial reduction in tuberculosis incidence prior to 
the introduction of antibiotics comprises an integral role in the continuing efforts to 
combat tuberculosis around the world.  
Mycobacterium Tuberculosis: Infection and Pathogenesis  
Mycobacterium tuberculosis is the most common etiological agent of tuberculosis 
in humans, although humans can also be infected with Mycobacterium bovis  and 
Mycobacterium avium. Like all bacteria, mycobacteria have a layer of peptidoglycan 
surrounding the plasma membrane. Mycobacteria have a thick lipid cell wall containing 
large amounts of mycolic acid. Other prominent molecules are 
lipoarabinomannan(LAM), a lipopolysaccharide, arabinogalactans, and glycolipids. 
Technically, mycobacteria are gram positive, but the cell wall excludes the Gram stain, 
leaving the bacteria only weakly stained. To address these challenges of microscopy, 
mycobacteria are identified in samples with an acid-fast or Ziehl-Neelsen stain
3
. The cell 
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wall is instrumental in bacterial immune evasion within unactivated macrophages and 
excludes many antibacterial compounds. The cell wall is also thought to be the reason 
why most mycobacteria can only replicate very slowly, as production of the thick lipid 
layer is very energy intensive. Embedded within the cell wall proteins, such as porins, 
proteins that help molecules get through the thick lipid layer. Unlike the lipids, these 
proteins are antigenic, recognized by T-cells, and the major component of the Purified 
Protein Derivative, PPD, that forms the TST
4
.  
MTB are intracellular pathogens that escape destruction by macrophages and can 
replicate within them
5
. Naive macrophages are able to phagocytose the bacteria, but the 
bacteria prevent the fusion of the phagosome with the lysome. Once phagocytosed, lipids 
from the mycobacterial cell wall, namely LAM, diffuse into the phagosome and other 
cellular membranes, fundamentally altering their properties and behaviors. Specifically, 
phagosomes embedded with LAM do not fuse with the lysosome. Inside the macrophage, 
the bacteria are temporarily protected from antibodies and other parts of the immune 
system
3
. Studies with mice infected with M. avium demonstrate that if tuberculosis 
spreads to the thymus, new T-cells do not respond to the presence of M. avium antigens. 
When the immature T-cells differentiate within the thymus, any T-cells that respond to 
“self” antigens are destroyed. Apparently, infected dendritic cells in the thymus present 
tuberculosis antigens as “self” antigens. When the T-cells produced by infected thymi 
encounter mycobacterial antigens, they do not release the INF-γ that activates 
macrophages and dendrites, as do T-cells from healthy thymi
6
. 
The majority of people infected with tuberculosis never become ill because the 





 T cells(helper T cells) specific for MTB antigens release cytokines, 
such as interferon (IFN)-γ, that activate macrophages. Activated macrophages have 
increased expression of NOS2, nitric oxide synthase 2, a protein that produces nitric 





cells are key to controlling the initial infection, CD8
+
 cells are necessary to prevent the 
bacteria from reactivating. CD8
+
 T cells kill infected macrophages and appear to also kill 
mycobacteria directly with granulysin and other compounds
8
. Studies in mice 
demonstrate that mice without an effect CD8
+ 
(killer T cells)  response have a delayed 
control of the bacterial infection (40 as opposed to 20 days), and that the bacterial 
population grows to a higher level before reaching a plateau than in WT mice. On the 
other hand, mice lacking CD4
+
 response are unable to control the infection at all, and 
quickly die off
9
. Immunosuppressive drugs that target tumor necrosis factor (TNF), result 







memory T cells (TEMRA cells), that suppress reactivation of tuberculosis
10
. Patients with 
inflammatory diseases such as rheumatoid arthritis who are treated with 
immunosuppressive drugs are at a greatly increased risk of tuberculosis reactivation. 
A specific immune response is key to controlling a tuberculosis infection; an 
improper immune response can be ineffective, as seen with naïve macrophages, or even 
pathogenic. For example, in patients with pulmonary tuberculosis, the majority of the 




Mycobacterium tuberculosis most commonly initially infects the lungs and forms 
a pulmonary infection, although the bacteria can infect wounds in other parts of the body. 
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Infection occurs when a person inhales small liquid nuclei laden with bacteria from a 
coughing individuals or some other form of aerosolization. Large droplets get trapped in 
the upper respiratory tract and are expelled by celia, thus only small droplet can cause 
disease
4
. From the initial site of infection, the bacteria can spread to most tissues in the 
body, including the brain, liver and bone
3
. If the bacteria enter the body through the 
lungs, the initial immune response can often contain the infection in a granuloma while 
the specific immune response builds up. If the granuloma is small enough, less than 3 
mm in diameter, the cellular immune system can penetrate the granuloma, killing infected 
macrophages, with the released bacteria able to be successfully destroyed by activated 
macrophages. If the granuloma is too large, it merely contains the bacteria, out of the 
reach of competent immune cells. In this low oxygen environment, the bacteria enter a 
semi-dormant state, able to reactivate and spread at a later time
4
. This state is referred to 
as a latent tuberculosis infection (LTBI). Patients with LTBI are diagnosed by a positive 
skin test but negative chest X-ray. Latent tuberculosis is treated with isoniazid for nine 
months (CDC 2003). Approximately 10% of LTBI cases later progress to active 
disease
12
. Active disease occurs when the bacteria escape from the granuloma and start 
replicating, causing the classic symptoms of night sweats, weight loss, and a persistent 
cough.  
 Based on these symptoms, a doctor who suspects tuberculosis will confirm the 
diagnosis with a tuberculin skin test (TST). This test, originally described by Koch, 
demonstrates whether or not the immune system recognizes tuberculosis antigens from an 
infection, either recent or past, with tuberculosis
2
. One modern advancement in diagnosis 
of LTBI comes in the form of the QuantiFERON-TB Gold In-Tube test (QFT). Since 
10 
 
QFT looks for the response of effector T-cells to  tuberculosis antigens rather than for the 
delayed type hypersensitivity reaction, it has several advantages over the traditional TST. 
First, QuantiFERON can differentiate between vaccinated and infected individuals. 
Additionally, individuals successfully treated for tuberculosis will have a positive TST, 
but can be shown to be negative by the QFT
13
. Finally, Quantiferon Gold is more suited 
for mass screenings or contact investigation, able to be administered and interpreted with 




 For patients with pulmonary tuberculosis, a sputum sample is placed on a slide 
and examined microscopically for acid fast bacilli. Culture and biochemical assays give 
definitive proof of a mycobacterium as well as identifying the species, such as M. 
tuberculosis or M. bovis 
15
. Smear microscopy is also used to monitor treatment and is 
often used as a proxy measure of infectiousness in a patient. Sputum conversion from 
positive to negative signals either a significant decrease in bacillary load or cavity 
closure, both of which indicate a reduction in infectiousness. In many ways, sputum 
smear microscopy meets the criteria for a perfect diagnostic. Smear microscopy is fast, 
with results available within an hour, cheap and has low infrastructure requirements, able 
to be performed in settings with inconsistent electricity or water. Nevertheless, smear 
microscopy does have limitations. First, smear microscopy is unspecific, unable to 
differentiate between Mycobacterium tuberculosis, Mycobacterium bovis,  and 
nonpathogenic Acid-Fast bacilli
1
. Additionally, children are rarely able to produce 
sputum, forcing clinicians to forgo microscopy and depend entirely on patient 
                                                 
1
 Some technicians with long experience with acid-fast microscopy perceive identifiable nuance between 
AFB based on bacillus size , clumping of bacteria, and relative width, but these distinctions can not be 
easily taught and standardized.  
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presentation. Smear microscopy can only reliably detect bacteria in sputum at a level of 
5,000/mL, a relatively high limit of detection. 
 Finally, smear microscopy cannot differentiate between live and dead bacteria in 
the lungs. Individuals receiving therapy often become culture negative before they 
become smear negative. Given the limits of smear microscopy as the standard point-of-
care diagnostic, as well as the challenges of phenotypic susceptibility testing, there is a 
future in alternative point-of-care diagnostics. 
The infectiousness of a tuberculosis patient depends on several factors, including 
proximity and time spent with contacts, number of contacts, bacterial load, and frequency 
of coughing. Due to the difficulty of measuring these variables after transmission has 
occurred, no good estimates of patient infectivity have been obtained from epidemiology 
evidence, such as the number of possible contacts who became infected. Escombe et al. 
attempted to remove those variable by pumping the air from a ward of HIV/TB 
coinfected patients over guinea pigs and testing the guinea pigs. The guinea pigs were 
later tested for tuberculosis, and the DNA fingerprint matched to the strains carried by 
patients in the ward. For patients not yet on therapy, patients produced on average 6.7 
infectious quanta/hr. Infectiousness varied greatly by patient, however, with one MDR 
patient producing 226 infectious quanta/hr. The only significant determinant of 
infectiousness discovered were MDR and smear-positive. Other factors may be involved, 
but the small sample size, 43 patients, limited the power of the study
16
. The results of this 
study contradict the controversial observation that MDR strains are less infectious than 





Streptomycin and isoniazid gave the first real hope for curing tuberculosis
2
. Soon, 
however, strains resistant to streptomycin began to arise. Since then, identifying and 
treating resistant strains has played a major role in combating tuberculosis world wide. 
Because the bacteria can reproduce inside host cells and remain dormant in a latent state, 
any drug treatment must last a long time to ensure that all of the bacteria have been 
eliminated. Standard treatment for active pulmonary tuberculosis can be completed in as 
few as six months. The first two months include pyrazinamide, ethambutol, rifampin, and 
isoniazid. These four front-line drugs are used because they are more effective and have 
fewer side effects than the second-line medications, which are only used if the first-line 
drugs are ineffective. Using these four drugs reduces the probability of developing 
resistance, giving a window during which to identify the susceptibility pattern of the 
isolate. If the isolate is pan-susceptible, rifampin and isoniazid are continued for the 
remaining four months. Complications, such as INH resistance or a reaction to 
medication, can extend the treatment longer. The only accepted reasons for extending 
therapy past 365 days are meningial involvement, disseminated tuberculosis in children 
under the age of 15, and rifampin resistance. These guidelines include suggested lengths 
of treatment, as well as the targeted number of doses.  Each suggested regimen is rated 
regarding whether it is based on expert opinion, one trial, or multiple trials
17
.  
Drug Resistance and Susceptibility Testing  
Culture is more sensitive than direct microscopy for tuberculosis diagnosis and 
also allows phenotypic susceptibility testing. Drug susceptibility testing is extremely 
important. Susceptibility tests for rifampin and isoniazid are prioritized as the most 
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clinically relevant, since they are front line drugs. In fact, MDR (multiple-drug resistant) 
tuberculosis is defined as resistance to isoniazid and rifampin, with or without resistance 
to other drugs. If resistance to rifampin and isoniazid is detected, second line drugs must 
be administered, with the potential for greater toxicity. XDR (Extremely Drug Resistant) 
is MDR plus resistance to a quinolone and at least one of the following drugs: 
kanamycin, capreomycin, or amikacin
51
. As culture-based sensitivity testing is quite 
slow, a clinician may have to adjust the prescription for a patient with a failing treatment 
regimen without knowing of the exact sensitivities of the isolate. If a person has a high 
load of bacteria resistant to two antibiotics, random mutations may allow a very small 
subpopulation to gain resistance to a third antibiotic. If a clinician adds that third 
antibiotic to the regimen, all of the bacteria resistant to only two antibiotics will die off, 
and the triply resistant strain will grow unchecked until the individual now carries a large 
bacillary load of bacteria resistant to three antibiotics. The process by which a population 
of bacteria resistant to a certain number of antibiotics gains resistant to further antibiotics 
is termed amplification of resistance
18
. The simplest rule of thumb to avoid the 
amplification of resistance is to never add a single drug to a failing regimen. The odds are 
extremely low that a single bacterium could develop resistance to two additional 
antibiotics through random mutation.
19
 
Patterns of drug resistance overlaid on drug intolerance can be complicated, so 
designing a successful drug regimen often requires an expert consult. Getting a patient 
with suspected resistance on the proper drug regimen quickly reduces the potential for the 
amplification of resistance to other antibiotics and reduces the time spent in isolation. 
Isolation is extremely expensive, especially if drawn out up to a month. Quickly 
14 
 




For isoniazid and rifampin, unlike ethambutol, the extent of resistance can vary, 
but there is a sharp distinction between susceptible and resistant strains. The bacteria do 
not gradually develop resistance to these antibiotics; rather, any individual bacterium is 
either resistant or susceptible. The susceptibility of an isolate changes as the proportion of 
susceptible to resistant bacteria changes. By definition, an isolate is resistant to rifampin 
or isoniazid if 1% of the bacterial population is resistant. The preferred method of 
phenotypic susceptibility method is making identical plates on Löwenstein-Jensen 
medium, both with and without antibiotics. The proportion of colonies on the antibiotic 
plate compared to the normal plate gives a measure of the resistance of the population. 
Mycobacterium tuberculosis grows very slowly, however, making culture very slow, 
expensive, and dangerous to laboratory workers. Culturing mycobacteria requires 
biosafety cabinets and special facilities with controlled air flow (12). 
 Isoniazid (INH) has been used to treat tuberculosis since the 1950’s, but its 
mechanism of action is still not completely understood. In general, INH blocks the 
synthesis of mycolic acids, which form the lipid coat of the bacilli. INH resistance occurs 
naturally in 10
-7
 bacteria of M. tuberculosis. Other (sub)species of mycobacteria, such as 
M. bovis, are innately resistant to INH. Multiple resistance mechanisms exist against 
INH. The mechanism first discovered involves mutations in katG, which codes for a 
catalase-peroxidase. Resistance can also stem from mutations in inhA, which codes for a 
protein in the mycolic acid synthesis pathway. InhA mutations, but not katG mutations, 
are associated with cross-resistance to ethambutol, another commonly used antibiotic. 
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Other INH resistance mechanisms remain to be discovered, as almost 20% of strains 
resistant to INH do not have a mutation in either gene (13). 
Rifampin was discovered as a broad-spectrum antibiotic in 1968. However, 
rifampin’s effectiveness against tuberculosis and fears of resistance arising from 
widespread use caused the health community to dedicate rifampin as a tuberculosis drug. 
Since then, rifampin has been a cornerstone of tuberculosis treatment
20
. Rifampin spreads 
easily through tissues, reaching the bacteria and diffusing through the cell wall. Rifampin 
binds the beta subunit of the RNA polymerase, exercising bactericidal activity as it 
blocks elongation of the transcript. Once elongation has initiated, rifampin no longer 
binds and does not inhibit transcription. The subunit, coded by the rpoB gene, is highly 
conserved across bacterial species, especially in the 12 residues that interact directly with 
rifampin.  
Other antibiotics used to supplement these core drugs are ethambutol, 
pyrazinamide, fluoroquinolones, and aminoglycosides. Ethambutol interferes with the 
metabolism of mycobacteria. Pyrazinamide is an analogue of nicotinamide that lowers 
the pH of the bacterial cytoplasm. Fluoroquinolones act against DNA gyrase and are used 
when resistance to a first line drug has been identified
21
. Aminoglycosides, which include 
Amikacin and Kanamycin, bind tightly to ribosomes and disrupt protein synthesis
4
. 
Bacteria are able to develop resistance to any single one of these antibiotic through 
random mutations, so proper drug management focuses on using a combination of 
antibiotics such that any individual bacterium would be unlikely to simultaneously 
develop resistance to all at the same time. Continuing research for novel antibiotics is 
underway, but clinicians and health policy officials recognize that the appropriate 
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framework for the use of antibiotics is necessary to prevent the widespread development 
of strains resistant to any and all antibiotics. 
Tuberculosis/HIV coinfection 
Impact of tuberculosis on HIV patients 
 Tuberculosis is one of the major opportunistic infections of HIV patients. 
Tuberculosis kills 30% of people with HIV. HIV patients who are infected with 
tuberculosis experience increased viral loads in both their blood and other organs. This 
phenomenon most likely occurs because immune activation stimulates viral replication. 
In response to an infection of tuberculosis, the immune system releases cytokines, such as 
tumor necrosis factor (TNF)-α, which stimulate viral replication
84
. Another contributing 
mechanism appears to be that immune activation in response to tuberculosis increases the 
proportion of CD4
+
 cells that express CCR5 and CXCR4, two receptors that HIV uses to 
gain entry into the cell. With more available host cells, the virus is able to replicate 
faster
22
. While all HIV patients are susceptible to tuberculosis, their risk of infection 
depends on their probability of coming into contact with someone with tuberculosis
23
. 
Impact of HIV on TB patients 
 Tuberculosis diagnosis and treatment is complicated by coinfection with HIV, 
particularly advanced stages of HIV. Because the traditional PPD skin test for 
tuberculosis measures an immune reaction to tuberculosis antigens, rather than testing 
directly for the presence of tuberculosis, individuals with severly depressed immune 
systems may have a false negative test
84
. Furthermore, the classic radiographic signs of 
tuberculosis on a chest x-ray stem from the accumulation of macrophages and T-cells 
around bacteria, with the subsequent tissue damage and cavitation due to inflammation. 
17 
 
Tuberculosis bacteria replicating unchallenged in the body of an immune compromised 
host do not cause cavitary lung tissue damage that is visible to a clinician. In fact, most 
tuberculosis patients with  CD4 count under 200cells/mm
3
 have normal X-rays
24
. Even 
sputum smears cannot reliably diagnose HIV+ patients with active pulmonary 
tuberculosis
25
. In immunocompromised individuals, TB disease progresses much more 
quickly than in individuals with a robust immune system. Rather than being confined to 
the lungs, TB is able to disseminate throughout the body, presenting atypical 
extrapulmonary forms of the disease. Given these complementary mechanisms, HIV+ 
individuals infected with tuberculosis have a 20 times higher annual probability of 
progressing to active disease than noninfected individuals,
26
 and that ratio reaches 170 for 
individuals with AIDS
84
. The increased susceptibility to tuberculosis can be observed as 
early as seroconversion and the susceptibility continues to increase and the CD4+ count 
falls. Initiating Anti-RetroViral Therapy (ARV), with the subsequent resurgence of CD4+ 
cells, somewhat mitigates the susceptibility to tuberculosis, but even HIV patients on 
ARVs are at an increased risk of tuberculosis than individuals without tuberculosis
27
. 
 Treatment of coinfected patients is also complicated. First of all, both 
HAART(Highly Active Anti-Retroviral Therapy) HIV treatment and tuberculosis 
medication involves taking multiple medications simultaneously to decrease the 
probability of the pathogen developing resistance. Patients taking up to eight different 
medications have increased chance for drug interactions and negative side effects, e. For 
example, rifampin activates CYP450 enzymes in the liver that speed the metabolism of 
many other drugs. Rifampin also blocks protease inhibitors, thus most TB/HIV drug 
regimens substitute rifabutin for rifampin
84
. Additionally, both HIV and TB drugs can 
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result in hepatotoxicity, or liver damage. Initiating HAART therapy increases the 
probability of the so-called Paradoxical Reaction(PR), wherein a patient undergoing 
effectibe anti-tuberculosis therapy experiences a worsening of symptoms. ART-induced 
PR is most likely due to the resurgence of the immune system, with subsequent 
inflammation and tissue damage that is symptomatic of tuberculosis. In the long-term, the 
PR is eventually reversed and treatment procedes successfully. For a person in a fragile 
state of health, however, the PR may be severe enough to cause death
28
.  Based on the 
severity of both diseases, a clinician might decide to delay initiation of treatment for one 
of the diseases.  
 From a public health perspective, the increased susceptibility of HIV patients can 
cause a surge in tuberculosis incidence in regions with otherwise effective tuberculosis 
programs and low baseline levels of resistant strains. In Botswana, despite consistent 
DOTS implementation, TB prevelance increase by 120% over a seven year period, 
almost entirely due to the rise of HIV
29
.  
Tuberculosis Control in Emergency Situations 
 Control of tuberculosis is further complicated by large upheavals due to either 
conflict or natural disasters. These upheavals present special challenges in both 
transmission prevention as well as continuity of therapy. The steady decline in 
tuberculosis incidence and mortality suffered a check during World War I. Health 
professionals recognized the problem and quickly instituted new interventions to address 
the rise in tuberculosis cases
2
. After hurricane Katrina, one fifth of individuals being 
treated for tuberculosis could not be located after the hurricane
30
. Treatment interruptions 
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present a worse prognosis for individuals. Incomplete therapy also poses a risk for the 
development of resistance to antibiotics, with broader public health implications.  
Pediatric tuberculosis 
 Tuberculosis behaves differently in children than adults. Children infected with 
tuberculosis develop disease in a matter of weeks or months, much faster than adults. 
Children are also more prone to develop extrapulmonary tuberculosis, including many 
deadly and debilitating forms of tuberculosis. Some tuberculosis control programs tend to 
overlook children, however, both because they are difficult to diagnose, and because 
children are not considered infectious
29
. Prompt recognition and treatment of pediatric 
tuberculosis not only protects the child, but also helps doctors and public health officials 
locate the infectious contacts of children before adults infected at the same time become 
sick.  
 Diagnosis of pediatric tuberculosis is difficult, often relying on clinical symptoms, 
a positive skin test, and a history of contact with an contagious adult. Children with 
pulmonary tuberculosis have difficulty producing sputum, and since the bacteria are often 
contained in sealed lesions,  only 5% of pediatric cases are smear positive. Furthermore, 
even under the best sample collection methods, only 40% of children with tuberculosis 
are culture positive. To overcome these diagnostic challenges, current US guidelines state 
that all children who live in the household of newly diagnosed adult cases of tuberculosis 
should be placed on precautionary regimens of isoniazid
31
.  
 Another measure aimed mainly at pediatric tuberculosis is the use of the 
BCG(Bacille Camile- Guillot) vaccine. The BCG vaccine is a live attenuated form of M. 
bovis. Much debate surrounds the safety and efficacy of the vaccine. The BCG vaccine 
20 
 
appears less effective in regions where there is a high likelihood of exposure to 
environmental mycobacteria, which is mainly in the tropical climates. While studies 
conflict on the measure of protection, most meta-analyses indicate that the BCG is 50% 
effective at preventing tuberculosis disease. While 50% effectiveness is rather small, the 
real power behind the BCG vaccine, and the main justification for its near global use 




 The BCG vaccine is not routinely used in the United States. Individuals 
vaccinated with the BCG will react to the PPD skin test, giving a false positive result for 
tuberculosis infection. Given the low incidence of tuberculosis in the United States, the 
ability to diagnose and treat subclinical cases of tuberculosis is considered more effective 
overall than potentially preventing disseminated tuberculosis in children
33
. BCG 
vaccination is also not recommended for individuals know to have HIV, due to an 
increased risk for an adverse reaction
34
. Finally, though the risk of adverse reactions to 
the vaccine are normally quite small, the rise of pediatric HIV has created a population of 
immunosuppressed children who can become sick from the attenuated bacteria.  
Development of New Vaccines 
 New vaccines are being sought, but these efforts face several challenges. First, 
Mycobacterium tuberculosis is a human pathogen, and finding an appropriate animal 
model poses a challenge. Mice, while cheap to infect and maintain, mount an immune 
response quite different from the human response. Guinea pigs are very susceptible to 
tuberculosis and die quickly, not demonstrating the specturm of disease observed in 
humans. Rabbits appear to be a more appropriate immunological model than mice or 
21 
 
guineau pigs, but research involving rabbits, as with guineau pigs, lacks the wide range of 
immunological tools available for mice
35
. Vaccines that show promise in one of the 
above models can then be tested with macaques, which pose a greater expense and 
biohazard to laboratory personnel. Another challenge in vaccine development is that the 
early immune response to tuberculosis infection, which is often successful in destroying 
or controlling the bacteria, is only starting to be understood
36
. Finally, triggering an 
appropriate immune response is especially important with tuberculosis, as many of the 
pathologies of tuberculosis are due to an improper immune response. 
Molecular tools for tuberculosis control  
 Molecular biology has introduced new tools in the fight against tuberculosis. 
DNA fingerprinting allows strain typing of tuberculosis, giving useful epidemiological 
information. For examples, DNA fingerprinting allows epidemiologists to determine 
whether cases occuring in the same region are the result of coincidence or whether they 
are clustered. Fingerprinting can also answer the question of whether an individuals with 
a second episode of tuberculosis is suffering a relapse of the previously treated strain, or 
whether the individuals has been reinfected by a new strain. Finally, fingerprinting can 
help identifiy false positive cultures and track down nosicomial transmission
37
.  
 There are several strategies for DNA fingerprinting of tuberculosis. In general, 
strain typing analyzes differences in non-coding DNA, which is not under selective 
pressure and is thus free to undergo steady change. In general, two isolates will match 
only if representing a recent transmisssion. IS6110 resriction fragment length 
polymorphisms (RFLP) fingerprinting was the first commonly accepted molecular 
method to assign epidemiological linkages. IS6110 is a movable element in the TB 
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genome that exists in multiple copies. The multible copies allow for frequent 
recomination, altering the DNA length between instances of the fragment. Because RFLP 
fingerprinting relies on an intact genome, PCR amplification cannot be used. Rather, an 
isolate must be grown in culture to the point that lysing the cells and treating the DNA 
with restriction enzymes specific for the IS6110 sequence will result in fragment in high 
enough quantities that they can be visualized when separated out on a gel. A newer 
method of strain typing, spoligotyping, is a PCR based system, and thus can analyze 
diagnostic specimens directly. Additionally, spoligotyping can differentiate between 
strains with less than five IS6110 elements
38
. 
Genotypic tests for Rifampin Resistance 
 Given the time delay and biohazard posed by culturing tuberculosis, molecular 
methods began to be sought for susceptibility testing, especially for rifampin. Over 90% 
of rifampin resistant strains are also resistant to isoniazid
39
. The rpoB gene codes for the 
beta subunit of the RNA polymerase, the target of rifampin. Mutations in the rpoB gene 
compose the major resistance mechanism for rifampin. Specific mutations cause specific 
levels of resistance, as well as having various cross-resistances to other antibiotics.
40
. 




 Gene sequencing is the gold standard in mutation detection. Sequencing identifies 
the exact mutations and allows silent mutations to be differentiated from amino acid 
substitutions. However, while sequencing is very accurate on a pure culture, it has trouble 
showing mutants that form a small percent of the bacterial population, thus 





. Many in house assays have been developed to quickly identify rifampin and 
isoniazid resistance in research laboratories. The DNA must be extracted from the 
sample. Some methods require the DNA to be extracted from a pure culture, but testable 
DNA can be extracted from sputum. In fact, DNA extracted from Ziehl-Neelsen stained 
slides can diagnose rifampin resistance by looking at substitutions in codons 516, 526, 
and 531 with 84% sensitivity
43
.  
 Although in house assays abound, clinical applications require a reliable, 
standardized assay
2
. The main commercial method developed is the reverse line probe 
assay. The sample DNA is extracted. The rpoB gene is amplified with biotinylated 
primers. The PCR product is incubated with a membrane strip, allowing it to hybridize 
with immobilized sequences representing either wild-type or mutant sequences for 
various codons. After washing, the hybridized sequences are visualized with streptavidin-
coupled enzymatic colorization. The streptavidin irreversibly binds the biotinylated PCR 
product. The entire procedure can be performed in two days. It detects mutations in 
mixed cultures. As with any PCR test, cross-contamination poses a threat of false 
positives, and must be rigorously controlled. INNO-LiPA Rif TB, a reverse line probe 
assay from Invitrogen, detects rifampin resistance with 100% specificity and 98% 
sensitivity
44
. A study performed in Rwanda using individuals with no background in 
molecular biology to run and interpret these tests demonstrates the field potential for 
molecular diagnostics
45
. Like other countries, Rwanda has received funding for treating 
MDR, but MDR cannot be treated until routine susceptibility testing is performed. While 
the commercial tests are currently prohibitively expensive for low-resource countries, the 
                                                 
2
 Despite the greater resources and training available in industrialized nations, FDA approval lags behind 
the rate of advances in technology, creating a gap between the development of new diagnostic technologies 
and their routine implementation (Personal communication, Dr. Kenneth Jost). 
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Foundation for Innovative Diagnostics (FIND) is subsidizing another line probe assay, 
the Genotype MTB-DR plus from Hain Lifesciences for use in low-resource countries
46
.  
Humans have battled tuberculosis for thousands of years. Several key advances in 
that battle include the isolation of Mycobacterium tuberculosis in 1882 and the 
introduction of antibiotics in the middle of the twentieth century. Arguably, some of the 
biggest advances have occurred in the past twenty years, as advances in technology have 
given unprecedented insight into the virulence and genetics of tuberculosis. In addition to 
furthering the scientific understanding of tuberculosis, advances in technology are 
creating new tools for tuberculosis vaccination, diagnosis, and treatment. Alongside an 
increased understand of details such as environmentally dependent expression of 
transcription factors has come an increase understanding that effective control of 
tuberculosis must also address the barriers to diagnosis and consistent treatment that 




II. Barriers to Timely Completion of Treatment of 
Mycobacterium tuberculosis in Texas 
ABSTRACT 
 Tuberculosis remains a serious problem across the United States (US) as well as 
in Texas. In 2006, 1585 new cases of tuberculosis (TB), comprising over 10% of cases in 
the entire US, were reported to the Texas Department of State Health Services (DSHS). 
The CDC Division of Tuberculosis Elimination has codified performance evaluation 
criteria to aid measures to control TB. In order to ensure the best quality care to patients 
and best utilize the resources of the state of Texas, DSHS decided in 2006 to focus on 
evaluating and improving the performance of Texas on a single measure, Timely 
Completion of Therapy (COT). Timely COT is the proportion of cases eligible to 
complete therapy in less than a year that successfully completed therapy in less than a 
year.  
 The purpose of the study was to look more closely at the 132 TB cases first 
reported in 2006 indicated as having completed therapy in greater than a year. Of the 116 
cases evaluated, 21(18%) had had erroneous information reported to DSHS and did not 
qualify as delayed completion of therapy. Of the remaining 95 cases, 41 were delayed 
due to medical factors, 25 were delayed due to noncompliance, and 18 were delayed due 
to a lack of coordination among care providers. Three additional cases had no 
determinable reason for delayed completion of therapy. While the mean therapy duration 
was 469.9 days, 42 cases (44%) finished therapy within one year and one month. Risk 
factors associated with delayed completion of therapy were homelessness, resistance to 
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isoniazid, HIV, extrapulmonary involvement, diagnosis in a correctional facility, and 
alcohol abuse.  
INTRODUCTION 
Barriers to Timely Completion of Therapy 
Treatment guidelines are supposed to be communicated to physicians who can 
rely and follow the guidelines. Nonetheless, some doctors continue to prescribe longer 
than necessary treatment regimens, increasing the cost and inconvenience of treatment. 
Doctors tend to prescribe longer regimens for patients with extrapulmonary tuberculosis 
or HIV, despite studies demonstrating that these patients can be successfully treated in 





Interruptions in therapy allow the concentration of antibiotics in the blood to drop, 
giving the bacteria a chance to develop resistance. Dangerous side-effects of the therapy 
are a significant cause of interruptions in therapy. For mild side effects, the importance of 
consistent tuberculosis treatment outweighs patient discomfort. Other side effects are 
more severe and even life-threatening, requiring treatment to be suspended until the 
responsible drug can be identified. One relatively common severe side effect is 
hepatotoxicity. One meta-analysis combined the data from 19 studies that evaluate the 
risk of hepatotoxicity due to INH or when combined with RIF. Alone, INH carries a 1.6% 
chance of hepatotoxicity, but combined with RIF carries a 2.7% risk of hepatotoxicity. 
Hepatotoxicity is more of a risk for patients with liver damage due to hepatitis or alcohol. 
Depending on the severity of the reaction, hepatotoxicity forces the physician to hold 
tuberculosis therapy until the drug responsible can be identified and removed from the 
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With such long regimens, patient compliance can be quite low. Patients either 
forget to take medication, or decide not to take medication. To combat the problem of 
noncompliance, the WHO recommends, and most countries implement, DOT, Directly 
Observed Therapy, where the patient is observed taking each dose of medication
50
 (8). 
DOT has been proven to increase completion
51
 and has had a positive impact on 
treatment in Texas. In the 25 cities and counties with over 100 new cases of tuberculosis 
in at least one year between 1990 and 1994, the jurisdictions with more cases tend to 
have lower 12-month completion rates. For example, Houston, TX had the fifth largest 
number of cases per year, and ranked near the bottom of 12-month completion rates, with 
only 50% completion rate before the large influx of federal funding in 1993 that 
supported the expansion of DOT programs. Dallas-Dallas County, El Paso, Ft. Worth-
Tarrant County, and Austin-Travis County on the other hand, average over 90% 
completion rates. Over the study period, Dallas rates of DOT increased ten-fold from 
4.9% to 49.4%, but the 12-month completion rate remained constant at 96%
52
. Most 
often, treatment is given free of charge. For patients with complicating life 
circumstances, such as homelessness, additional incentives and enablers to encourage 
treatment, such as food stamps and assisted housing, may be made available
53
 . For 
completely intractable situations, patients may be treated as in-patients at the Texas 
Center for Infectious Disease (TCID) and Heartland Medical Center, both located in San 
Antonio, as well as the UT Tyler tuberculosis hospital. Given the enormous cost of in-
patient stays of over six months, this final treatment option is a last resort.  
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To help simplify the efforts to control tuberculosis, the CDC Division of 
Tuberculosis Elimination published 10 fundamental recommendations with 
corresponding performance indicators. Once reliable data on those indicators are 
available, each state, city and provider is encouraged to set performance goals based on 
the indicators. The CDC recommends focusing on evaluating improving one indicator at 
time. In 2006, Texas chose “Timely Completion of Therapy,” and set a goal of 83% by 
the year 2010. The nationally set goal for 2015 states: “To account for gaps in therapy, 
which may occur because of drug intolerance or nonadherence, the performance indicator 
is for 90% of patients with TB caused by a drug-susceptible isolate to complete a course 
within 12 months of initiation of treatment 
50
.”  
The purpose of this study was to examine the barriers to timely completion of 
tuberculosis therapy in Texas. Identifying the major barriers to timely completion of 
therapy can help suggest more effective strategies to overcome these barriers and meet 
national and state performance goals. 
METHODS 
Study Population  
This study looks at confirmed cases of tuberculosis reported in 2006. The CDC reports 
13,767 confirmed new cases in the entire United States. Over ten percent, or 1,585, of 
those cases were identified in Texas
54
. One hundred and thirty two of those cases eligible 
to complete therapy within 365 days did not complete therapy during that time, but had 
successfully completed therapy by the time of this study. Exclusion criteria include death, 
M. bovis resistant to pyrazinamide, resistance to rifampin, meningeal involvement, and 
disseminated tuberculosis in children under the age of fifteen. All of these criteria greatly 
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complicate therapy, and a patient with one of these risk factors is expected to require 
more than a year of therapy. 
Data Sources 
Cases meeting the criteria for this study were first identified through TIMS, the 
database for tuberculosis cases in Texas. Additional patient information, mainly the DOT 
records and the progress reports, were requested from the county health department that 
reported the case. TIMS contains both social information (such as housing status, 
substance abuse pattern, date of entry into the United States) as well as medical 
information (HIV status, primary site of tuberculosis, start and completion of therapy 
dates). Additional information, such as interruptions in therapy, drug intolerance, and 
other sites of disease can be gleaned from the DOT records and the progress reports. 
Selected information concerning the cases was gathered from these sources into a new 
database for analysis. 
Data Analysis 
Initially, the start and completion of therapy dates listed in TIMS were confirmed 
based on the information in the DOT records. If the revised therapy duration was less 
than 366 days, the case was removed from the study pool. Additionally, if factors such as 
meningial involvement that disqualify a patient from completing therapy were discovered 
in the progress notes, the case was removed from the study pool. Based on the progress 
notes and DOT records, an underlying reason for delayed completion of therapy was 
assigned to each patient. These reasons fit into four major categories: lack of coordination 
between health providers, medical complications, compliance issues, and provider 
decision. County health departments take primary responsibility for following patients 
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with tuberculosis, but when patients are hospitalized, incarcerated, deported, or move, 
other health entities take partial or complete control over patient therapy. Medical 
complications may consist of medicine intolerance, extrapulmonary spread, resistance to 
isoniazid, or poor response to therapy. Patient noncompliance occurred both with and 
without DOT. Finally, provider decision included any reason not mentioned above that 
made the provider continue therapy past 365 days. The most common barriers to timely 
treatment completion were identified. 
Using the data available through TIMS, the odds ratio of delayed completion of 
therapy based on risk factors was determined. The risk factors examined in this analysis 
were HIV status, housing status, substance abuse, age, site of disease, diabetes status, 
country of origin, and previous history of incarceration. Data analysis was completed 
using Microsoft Excel and Access. 
RESULTS 
A review of TIMS revealed 132 cases eligible to complete therapy in less than a year who 
were treated for greater than a year. One hundred and sixteen of the 132 cases were 
included in the study based on DOT logs and progress notes, however, the DOT logs and 
progress notes were not received for 16 cases.  Twenty one additional cases were 
removed from the study following a review of the more accurate information available in 
the charts.  Figure 2 examines the 132 cases originally included in the study.  
A careful look at the data revealed that record errors inflated the number of cases 
that were reported as delayed completion of therapy. As seen in Figure 3, minor errors in 
start and stop dates changed the reported length of therapy for 15 cases, but did not result 
in their removal from the study population. Major errors resulted in 21 cases being 
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removed from the study population either because the case had completed therapy in less 
than 365 days, or because the case fit the study exclusion criteria. The specific errors are 
shown in the bar on the right.  For twelve cases, the closure date was listed as the stop 
therapy date. Four cases had the prescription date listed as the start date, three met 
exclusion criteria, and 2 had the wrong year recorded. The rest of the results below 
analyze the final 95 cases included in the study.  
Figure 4 shows how many days the 95 cases took to complete therapy. Sixteen 
cases completed therapy within one year and one week. Almost half of the cases finished 
within one year and one month. If those cases had had attention focused on completing 
therapy within one year, along with successful treatment, the number of cases of delayed 
COT in 2006 would have been closer to 50 rather than 95. The mean of 469.9 days is 
skewed by small number of cases that took very long time to complete therapy.  
Based on the DOT logs and progress notes, each case was assigned a reason that 
resulted in delayed completion of therapy. Only the single most important contributing 
factor was counted. For example, a patient that missed a few doses over the holidays was 
not listed as noncompliant if the real reason why they took longer than a year to complete 
therapy was that they were resistant to INH.  
The individual reasons for delayed COT were grouped into the convenient 
categories seen in Figure 5.  Fifty-two percent of the cases of delayed completion of 
therapy were rooted in some medical issue.  Patient noncompliance, 26%, and lack of 
coordination between health providers, 19%, accounted for most of the rest of the cases. 
Three percent of cases had no apparent reason for delayed completion of therapy and 
were listed as delayed completion of therapy due to provider decision.  
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Figure 6 breaks down the medical reasons that contributed to delayed completion 
of therapy. Forty-nine cases in total had medical issues that led to delayed completion of 
therapy, but some patients were counted in more than one category. For instance, a case 
of tuberculosis of the spine that was resistant to isoniazid was counted as both 
Bone/Spine and INH-R. Fourteen cases with bone and joint TB and 6 with disseminated 
disease completed their therapy in more than one year as did 33 cases who experienced 
complications from the therapy.  The first two medical reasons, involved with site of 
disease, appear at time of diagnosis. The last three become an issue during treatment and 
can extend therapy for a patient who was initially diagnosed for less than one year. The 
most commonly encountered complication of intolerance was hepatotoxicity. According 
to the guidelines, these medical issues, including bone and joint tuberculosis should not 
push therapy past one year. Nevertheless, physicians are hesitant to treat these patients 
for less than one year. 
Figure 7 shows the 25 patients for whom noncompliance was the reason their 
therapy was delayed. Noncompliance of patients occurs when the patient moves without 
informing the health department, misses DOT appointments, refuses medication, or 
otherwise obstructs treatment. Nonadherence to medication continues to challenge 
successful completion of therapy, even after the widespread adoption of directly observed 
therapy.  It was not possible to verify that only 3 patients were no-compliant with self 
medication because the missed doses were self-reported.   
Sometimes, a lapse in TB therapy occurs due to a lack of coordination between 
care providers, as illustrated in Figure 8. One difficulty encountered in providing 
consistent care occurs when a patient is incarcerated or released from jail, moves to the 
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jurisdiction of another health department, or is admitted to the hospital.  These cases fall 
into one of two categories: 1) the patient did not receive therapy from new provider once 
they moved, or 2) the patient received therapy in hospital or another county, but when 
they moved, the new health department decided to restart treatment. Both of these issues 
stem from a lack of communication and trust between care providers.  
A large part of the story of delayed COT is interruptions in therapy. As seen in 
Figure 9, interruptions varied in length from less than 30 days to more than 300 days and 
occurred for various reasons. Some of the major reasons are noncompliance, reaction to 
the medication, complications due to another medical condition, and incarceration. 
Depending on when during therapy the interruption occurred as well as how long the 
interruption lasted, the physician will decide to either add the missed doses to the end of 
treatment, or to restart therapy from the beginning. As you can see in the bar on the left of 
the graph, 34 cases had minimal interruptions in therapy but still took longer than a year 
to complete therapy. Generally, those were cases of extrapulmonary tuberculosis who 
were initially prescribed for twelve months of therapy followed by a smooth course of 
therapy.  
Risk Factors 
By comparing the characteristics of those who had delayed COT with those who 
completed therapy in less than one year, we can identify risk factors related to delayed 
COT. Risk factors are characteristics that are present at diagnosis that are statistically 
associated with delayed COT. Knowing significant risk factors can help a care provider 
be aware of which cases are in danger of delayed COT. Risk factors can include 
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demographic characteristics, behavioral and lifestyle factors, concurrent medical 
conditions, laboratory results, and the presentation of the disease.  
There was not a statistically significant difference for eight of the risk factors 
when comparing those who completed therapy on time and those with delayed 
completion of therapy. Four demographic characteristics, age, gender, ethnicity, and 
immigrant status were not predictive of delayed COT. Disease factors that did not 
influence timely completion of therapy included smear positivity and concurrent diabetes 
mellitus. Lifestyle factors that were not significant include previous history of TB and 
residence in a long-term care facility such as a nursing home.  
Figure 10 presents the risk factors that were found to be statistically significant, 
including the strength of the association between the risk factor and delayed COT. They 
include both lifestyle factors, such as homelessness, diagnosis in jail, alcohol abuse, and 
unemployment, as well as medical factors such as resistance to isoniazid, HIV, and 
extrapulmonary involvement. These risk factors are not completely independent- for 
instance, a large proportion of the homeless individuals are also unemployed.  
DISCUSSION AND FUTURE DIRECTIONS 
What main conclusions can be drawn from these results, specifically related to 
augmenting the proportion of cases who finish therapy in less than a year? With a 2006 
performance of 81.4% of patients achieving timely completion of therapy, Texas is  close 
but still short of the Texas 2010 goal, and still more than 10%  away from the national 
goal for 2015 for this indicator. This study examined the reasons why 116 patients took 
longer than the recommended year to complete therapy for tuberculosis. This study dug 
deeper than the information reported to the DSHS, going back to the original DOT logs 
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and progress notes. This approach revealed that a large percent of the records had 
misreported data. Misreporting the case closure date as the stop therapy date made the 
biggest difference when therapy was completed outside of the supervision of the 
reporting entity, demonstrating the importance of coordination between health providers. 
Simply tightening up reporting practices will not only improve the accuracy of the 
records in general, but will let Texas get proper credit for all of the cases that are treated 
on time.  
An analysis of the length of therapy for the 95 cases of delayed COT reveals that 
while some of the cases have extremely drawn out therapy due to complicating factors, 
17 percent finished within a year and one week. The analysis further suggests that a 
focused effort could bring almost half of the cases under a year of therapy, allowing 
Texas to reach the national goal of 90% completion by 2015. This improvement might be 
accomplished by the health department communicating the value of timely COT to the 
providers.  
An examination of risk factors revealed that homelessness is the strongest 
predictor of delayed completion of therapy. Physicians and care providers are already 
aware of the challenges presented in providing continuous care to a person without a 
permanent address. Two other risk factors were statistically associated with delayed 
completion of therapy because physicians use those conditions, such as HIV and 
extrapulmonary involvement, to prescribe for 12 months or longer.  
These insights suggest several concrete measures that can be taken to improve 
Texas’ performance on the performance evaluation criterion. Unlike doctors, who only 
see patients one at a time, health departments, both at the county and the state level, can 
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see a bigger picture and approach tuberculosis strategically. There will always be cases 
with complications both medically and socially that will be treated in over one year. 
Many other cases, however, could be treated within a year with a small amount of 
focused effort.    
 Future studies at DSHS semester will look at cases who completed therapy at 
least once, but then suffered a relapse of tuberculosis. Some of the questions asked will 
be whether the second disease is a reactivation of the old strain of tuberculosis or was the 
result of a new exposure to tuberculosis. Additionally, the risk factors associated with 
relapse will be identified, in part to determine whether some of the same factors that 
cause delayed COT also increase the probability of a relapse. For example, if patients 
with extrapulmonary tuberculosis are predisposed to suffering a relapse, then perhaps 
doctors are justified in treating them for longer periods of time.  
According to the recommendations, patients with TB in the bone or joints, or 
patients with HIV can be successfully treated within one year. Nevertheless, physicians 
are hesitant to treat these patients for less than one year. A survey of physicians in Texas 
could show whether the doctors are aware of the current recommendations. Further 
studies demonstrating the effectiveness of nine months of treatment might be more 
convincing to physicians hesitant to prescribe shorter therapy for patients with 




III. A Retrospective Analysis of Rifampin-Resistant 
tuberculosis in Afghanistan 
ABSTRACT 
The countries with the highest burden of tuberculosis are often those with the least 
resources available to combat it, challenging global efforts to stop tuberculosis. 
Afghanistan, for example, faces a high burden of tuberculosis in a low-resource country. 
Little data exists concerning the rate of drug resistance, a key factor in both planning and 
implementing public health interventions. This study used resistance conferring 
mutations in the rpoB gene as a surrogate marker of rifampin resistance. With an initial 
sample of 511 sputum slides representing approximately 5% of cases of tuberculosis 
diagnosed in the first quarter of 2008, full sequences of the region of interest were 
obtained for 136 samples. The results of this study give the first survey data of rifampin 
resistance across Afghanistan, as well as suggesting further implications concerning the 
potential benefit of molecular diagnostics in low-resource settings.  
INTRODUCTION 
Multi-drug resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to 
isoniazid and rifampin, with or without resistance to other antibiotics. Isoniazid and 
rifampin are considered front-line antibiotics due to their relative effectiveness and low 
toxicity compared with other antibiotics. Swift diagnosis of MDR-TB is important both 
clinically and in term of public health. Once diagnosed, MDR-TB can be properly 
treated, leading to a better outcome for the patient and preventing further transmission of 
resistant strains
55
. Improperly treat MDR-TB can result in the amplification of resistance, 
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whereby an isolate resistant to a certain subset of antibiotics gains resistance to further 
antibiotics, eventually leading to extremely drug resistant tuberculosis (XDR)
56
.  
Molecular diagnosis of rifampin-resistance in TB proves to be a general marker 
for multi-drug resistance for two reasons. First, rifampin monoresitance, isolates that are 
resistant to rifampin but susceptible to isoniazid, is rare; a global survey found that 95.4% 
of rifampin resistant strains were also MDR
57
. Secondly, 90% of tuberculosis strains 
resistant to rifampin contain a mutation in a 308 bp region, which includes an 81bp 
“hotspot”, near the middle of the rpoB gene, making this gene a good predictor of 
rifampin resistance.
58
 In contrast, only 67% of isoniazid resistance is detectable by 
mutations found in katG
59
. However, the proportion of rifampin-resistant isolates that are 
also MDR,as well as the frequency of specific mutations, varies with geographic area, 
necessitating caution when interpreting such results.
60
 
Molecular techniques carry the advantage of much faster results than conventional 
phenotypic susceptibility testing, as well as reduced exposure to infectious materials
61
. 
Another advantage over culture-based sensitivity testing is that PCR-analysis can be 
preformed on non-viable bacteria
62
. DNA extracted from Zhiel-Neelsen stained slides has 
been used to detect and type tuberculosis
63





The slides can be stored and transported at room temperature, reducing logistical 
challenges.   
Afghanistan is twenty-second on the WHO list of high-burden countries, with an 
estimated burden of 168 cases/100,000 residents/year. Afghanistan is one of the few 
remaining countries in the world with not survey on the extent of MDR-TB to date, and 
drug susceptibility tests are not routinely preformed
66
. Multiple dynamics complicate 
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efforts to predict the rate of MDR-TB in Afghanistan. For example, Afghanistan 
neighbors many countries, including former Soviet states, with a high burden of MDR-
TB, suggesting that travel between Afghanistan and its neighbors with a high burden may 
increase the rate in Afghanistan. On the other hand, Afghanistan has a relatively young 
anti-tuberculosis program, and there is no pressure for untreated tuberculosis to develop 
resistance, suggesting that Afghanistan might have a low burden on MDR-TB. In the 
most comprehensive attempt to unravel these parameters, Zignol et. al. used a 
mathematical analysis of factors contributing to MDR-TB in over 70 countries to 
estimate the rate of MDR-TB in countries that had not been surveyed, suggesting 
Afghanistan may have a rate of 3.0% of all TB cases, both new and previously treated.
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However, a study conducted at the National Research Institute of Tuberculosis and Lung 
Disease, the national TB referral center in Iran, found that 23% of TB isolated from 
Afghan patients was phenotypically MDR
68
. The rate of tuberculosis is higher for 
Afghans living in Iran than that of native Iranians.
69
 The rate of MDR among Afghans in 
Iran is not necessarily representative of the local population of Afghanistan, in part 
because Afghans living in Iran as refugees are more likely to have interruptions in 
therapy that allow resistance to develop.
70
 In Afghanistan, the diagnosis and treatment of 
tuberculosis is shared between many organizations
71
. Diagnosis relies upon clinical 
examination, along with Zhiel-Neelsen-stained sputum smears. The slides from clinics 
are sent to regional laboratories for quality control once every quarter. As routine 
susceptibility testing is not available in Afghanistan, clinicians infer drug-resistance from 
treatment failure (defined as a positive sputum smear after five months of treatment).  
40 
 
Studies demonstrate the feasibility of molecular analysis of tuberculosis in low-
resource countries. Even so, cost remains a major barrier to the routine implementations 
of molecular techniques for tuberculosis analysis in the developing world
72
.  
Herein, we provide the first national survey of rifampin resistance within the 
country of Afghanistan. Furthermore, this study represents the first use of molecular 
markers to identify rifampin resistant strains in Afghanistan. Resistance conferring 
mutations were present in twenty-one samples, representing thirteen of the twenty-six 
provinces for which data was obtained.   
METHODS 
Slides were obtained from the Quality Assurance Program at the National 
Tuberculosis Program of Afghanistan with IRB approval from both the University of 
Texas and the Afghan Ministry of Public Health. Each quarter, every laboratory that 
performs smear microscopy sends a portion of their slides to a regional laboratory for 
blind cross-checking. All slides are graded by a technician, then blindly cross-checked at 
a regional lab, and graded a third time if the first two grades disagree. Slides from every 
province in Afghanistan were included in this study, matched with the clinic of origin. 
The grades of the slides were not provided for most of the slides, however.  Some small 
clinics with less than five positive slides during the quarter send all of their positive slides 
for cross-checking. Larger health centers which diagnosed over 150 smear positive cases 
in that quarter send around 15 slides, with no standard slide selection procedure. Thus, 
smaller clinics are disproportionately represented in the sample. 
DNA material was recovered from the slides using the procedure described by 
Suresh, et al.
73
 The mineral oil was removed with xylenes (Figure 11). 50 ul of distilled 
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water was used to wash smear scrapings into an eppendorf tube. 10% Chelex was used to 
precipitate the cell fragments out of solution as well as remove potential amplification 
inhibitors such as metal ions
74
. The tubes were boiled fifteen minutes at 97C, then 
cooled and centrifuged. In the protocol described by Suresh et. al., the supernatant was 
used directly in PCR reactions. Initial DNA samples did not amplify, however, indicating 
the presence of inhibitors. Subsequently, all DNA samples were purified using phenol-
chloroform extraction followed by .3M NaOAc ethanol precipitation, desiccated and 
resuspended in a total of 100 ul.  
Heminested amplification 
Methods for a multi-stage PCR were originally described by Williams, et. al. with 
the following modifications.
75
The first stage consisted of 25 ul reaction (.2uM dNTP, 
2mM MgCl2, 1X PCR buffer, .2ul Platinum Taq (Invitrogen) forward (rpoB105) and 
reverse (rpoB293)primers, and 5 ul of purified slide DNA). Initial denaturation was 
performed at 94°C for 5 min, followed by 25 cycles of 95°C for 1 min, 62°C for 1 min, 
and 72°C for one min. Afterwards, 75 ul of the second stage master mix, (.2uM dNTP, 
2mM MgCl2, 1X PCR buffer, .2ul Platinum Taq (Invitrogen) forward (rpoB105) and 
reverse (rpoB273)), was added to the reaction and cycled for thirty more cycles with an 
annealing temperature of 65°C. Amplification was checked by agarose gel for the 193 bp 
product (Figure 12), and amplified samples were PCR purified using a PCR-Clean Up kit 
(Biosci), then sequenced at the Core facility of the University of Texas at Austin using 




In order to estimate the prevalence of MDR-TB in Afghanistan, diagnostic 
sputum slides were obtained from the Quality Assurance Program of the National 
Tuberculosis Program. Tuberculosis DNA was extracted from the slide material, and the 
rpoB gene mutations determined by sequence were used as surrogate markers of MDR. 
Full sequences of the region of interest were obtained for 136 of the 511 samples, 20 of 
which contained resistance conferring mutations (Figure 13). Although samples from 
almost every province were collected and tested, for some provinces, no sequencing data 
was obtained, because those provinces had relatively fewer slides in the sample, and none 
of the DNA from those slides amplified. 
Since both the province and clinic of origin was known for each sample, samples 
with resistance-conferring rpoB mutations had a known geographic origin. According to 
the WHO country profile of Afghanistan, the Southern, North-Eastern and Eastern 
regions of Afghanistan have the highest case notification rate of tuberculosis, the same 
regions that also show the highest rates of rifampin-resistance in this study (Figure 14). 
High levels of undiagnosed MDR can increase the total incidence of tuberculosis in a 
population, even with otherwise competent management, as observed in the New York 
epidemic of the early 1990’s
76
.  
TCG531TTG is the most common mutation encountered globally among rifampin 
resistant strains of tuberculosis and was also the mutation most frequently encountered in 
this study (Figure 15). In these samples, however, 11 of the 16 mutant sequences had the 
parallel silent mutation TTC514TTT. These samples may represent a dominant strain of 
rifampin-resistant tuberculosis that has spread among individuals in Afghanistan. 
Alternatively, these results may represent PCR cross-contamination. Strain typing the 
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original DNA could differentiate between these two scenarios: if the samples with the 
same mutations belong to the same superfamily, they most likely represent the same 
resistant strains. On the other hand, if the samples with the same two rpoB mutations 
belong to different families, the similarity is due to PCR contamination. Unfortunately, 
after testing the rpoB  sequence in this study, insufficient tuberculosis DNA remained to 
test further. 
DISCUSSION 
In conclusion, PCR analysis of rifampin resistance approaches the accuracy of 
conventional methods. As well, once the DNA has been isolated, it is stable, allowing 
future analysis, such as sequencing or spoligotyping. Using the Zhiel-Neelsen slides 
provides an easy way to store and transport the samples, allowing for a greater sample 
size. These results demonstrate the proof of principle that DNA recovered from slide can 
be used to test rifampin resistance. As well, this study demonstrates the feasibility of a 
national screening program based on molecular analysis of sputum smears, utilizing the 
existing infrastructure. Data from a national survey of MDR can  help strategically plan 
MDR-TB interventions in Afghanistan.  
Compared with a binary resistance test, sequencing offers the advantage of 
additional epidemiological data. For example, one particular mutation (TCG531TGG) 
was present in two samples. Given the low probability of any specific mutation 
occurring, there exists a chance that those two samples are epidemiologically linked. The 
fact that these samples were collected in neighboring provinces, and one of the samples 
was collected in a district bordering the other province, further suggests that the two 
samples represent the same resistant strain. The epidemiological link cannot be 
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definitively established, however, as information on individual patients was excluded 
from the study. The two samples might represent unrelated cases, members of the same 
household, or even the same individual who sought treatment at two separate clinics. 
One sequence, from a sample from Takhar Province, aligned more closely with 
Nocardiopsis species than Mycobacteria in a BLAST search. As this environmental 
actinomycete is not normally associated with human disease, the bacteria probably got on 
the slide from a environmental contaminations.  
This study found much lower PCR amplification frequency than that described by 
Suresh. Contributing factors may include differences in sputum smear preparation and 
staining, differences in storage conditions, or relative paucity of bacteria present on the 
slides. Additionally, the freeze-thaw cycles encountered during the transport of the 
isolated DNA may have damaged the integrity of the DNA. Finally, the primers used in 
this study may have had a lower efficiency than those used by Suresh.  
Sequencing the gene gave an unbiased look for the mutations viewed that are 
associated with rifampin resistance in Afghanistan. While the numbers of mutant strains 
encountered in this study are too small for statistical significance, several conclusions can 
be drawn. First, the mutations found were those that appear most commonly throughout 
the world. These mutant alleles are targeted in commercial mutation detection kits such 
as Inno-Lipa-RifTB and MTBDRplus from Hain, which remove the need for a 
sequencing step.  
Currently available molecular tests for drug resistance are still dependent on PCR 
machines and further equipment, limiting their effectiveness for point of care diagnostics. 
This study also shows the potential danger of sample contamination, undermining the 
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reliability of results. Nevertheless, compared to the alternative of conventional 
phenotypic susceptibility testing, molecular susceptibility testing still carries multiple 
advantages. First, when transporting sputum specimens with viable bacteria is logistically 
impossible, the only alternative is for the patients to travel to the nearest reference 
laboratory to give the sample for susceptibility testing. The personal expense to these 
patients is inconvenient if not prohibitive. Comparatively, mailing a week’s worth of 
slides at a time is a minor challenge. Secondly, PCR contamination is detectible with 
proper controls, and presents a danger only for the integrity of the results. Contamination 
in culture-based systems, on the other hand, jeopardizes both the integrity of the results, 
as well as the health of laboratory workers and the general public, as drug-resistant 
strains are grown in pure culture.  
Improvements in technology will continue to make molecular testing cheaper, 
faster, and less dependent on expensive infrastructure. Molecular testing holds potential 






IV. Detection of DNA by Strand Displacement and G-
Quadruplex Peroxidase Activity 
ABSTRACT 
 As previously discussed, molecular methods can be cheaper, faster, and safer than 
conventional susceptibility testing for rifampin-resistant tuberculosis. Molecular methods 
are also useful for the initial diagnosis and subsequent evaluation of Mycobacterium 
tuberculosis. The goal of this project is to develop a low-cost, point-of-care visual 
detection mechanism for both TB DNA in general and rifampin-resistant alleles in 
particular. This research successfully demonstrated the proof of principle that protein 
independent amplification modules can provide a visual signal to indicate the presence of 
a specific nucleic acid, with discrimination to the point of a single nucleic acid.  
INTRODUCTION  
 Although molecular methods to detect both MTB complex DNA as well as 
specific antibiotic resistance marker show great promise, there are still limitations. The 
vast majority of molecular detection techniques depend on PCR. PCR requires a 
thermocycler, which represents an initial investment, as well as polymerases, which much 
be stored in a freezer and maintained in a cold chain. As well, PCR products require some 
form of subsequent analysis, with further costs and infrastructure requirements.  
 The diagnostic mechanism has three components: 1) Sequence specific DNA 
detection 2) Non-enzymatic signal amplification with strand displacement and 3) a G-




 Strand displacement is the process by which an invader strand is able to replace 
one strand in a nucleic acid duplex in a two step process. In the first step, the invader 
strand binds to a single-stranded portion of the duplex, termed the toe-hold. The second 
step is branch migration, where the invader strand replaces one of the strands in the 
duplex, one or two bases at a time. Because the energy of the bond created is equal to the 
energy of the bond broken, branch migration is an energy neutral and reversible process. 
Because strand displacement is energy neutral, it can isothermally separate a DNA hybrid 
that otherwise would be stable to a very high temperature. 
 Strand displacement can also be used to amplify a signal. Zhang et al. created a 
catalytic circuit entirely based on strand displacement
77
. In brief, the output strand is 
originally hybridized to a dock, leaving a toe-hold of several base pairs on the dock. The 
output strand has an overhanging region that is involved in downstream processes but 
which is inactive while the output is bound to the dock. A fuel strand, also 
complementary to a sub length of the dock, is present in excess concentration, but is 
unable to displace the output at a rate of any significance as the fuel does not match the 
toe-hold displayed on the dock. The invader strand functions as a catalyst, binding to the 
toe-hold on the dock and displacing the output, but leaving a corresponding toe-hold on 
the other end of the dock. As this process is reversible, the output could potential rebind 
to the dock and displace the catalyst. Given the excess amount of fuel, however, the fuel 
is more likely to bind the toe-hold than the output, which is then free to activate the 
reporter. The fuel binds the toe-hold and displaces the catalyst, which is then free to 
displace another output strand. Through this iterative process one molecule of catalyst 
can release multiple strands of output.  
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 As the strand to be displaced can be easily labeled, strand displacement can be 
used as a proxy measure for the presence of an invader stand. The reporter strand can be 
labeled in a variety of ways that each has its own properties, including price, equipment 
required to detect the label, and sensitivity of the label. Labels that have been used 
include radioactivity, fluorescence
78
, and electronic beads
79
. 
Visual Detection using G-Quadruplex Peroxidase 
 Sequences rich in guanine are able to form both intermolecular and intramolecular 
quadruplexes, wherein each guanine forms hydrogen bonds with two adjacent strands. 
Adjacent strands may be either parallel or antiparallel. The G-rich telomeric sequences 
have been shown to form physiologically significant G-quadruplexes in vivo. These G-
quadruplexes block telomerase activity and must dissociate in order for the telomeres to 
be elongated. Compounds that stabilize G-quadruplexes show promise as a means to limit 
cell proliferation and combat cancer
80
. Besides role in telomeres, G-quadruplexes have 
additional interesting properties. In particular, G-quadruplexes can associate with hemin 
and demonstrate peroxidase activity
3
. Peroxidases split hydrogen peroxide, producing 
oxygen radicals which pull electrons away from any neighboring reducing agents. The 
stability of the G-quadruplexas well as a parallel intramolecular conformation largely 
determines the strength of its peroxidase activity. Cheng et al. examine the kinetics of a 
variety of natural and designed G-quadruplexes and found that the EAD2 quadruplex, 
(CTG3(AG3)3A) exhibited the highest rate among the sequences measured
81
.  
 Peroxidase activity has been harnessed to produce a colorimetric signal by using a 
reducing agent whose color depends on its oxidation status. ABTS is a commonly used 
                                                 
3
 Although the peroxidase activity of G-quadruplexes was first observed in vitro, Cheng et. al suggest that 
G-quadruplex peroxidases may be responsible for some of the oxidative cellular injury observed in the 
presence of hemin. 
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substrate, clear in its reduced form, and deep blue-green when oxidized. The color change 
can be observed qualitatively or measured quantitatively by reading the absorbance at 
414 nm on a spectrophotometer. Weizmann et al.
82
created a DNA detection mechanism 
using a G-quadruplex reporter, with amplification dependent on two protein enzymes, a 
polymerase and an endonuclease.  
 In the circuitry designed by Xi Chen (Figure 16) and tested in this research, part 
of the quadruplex sequence is bound to a separate dock sequence, preventing quadruplex 
formation and peroxidase activity. When the dock strand is displaced by t he output 
strand of the amplification process, the quadruplex can fold and peroxidase activity can 
be observed.  
METHODS 
 Sequences were ordered from IDT and resuspended in ddH2O. Because 
experiments with fluorescence demonstrated non-specific absorption of DNA at low 
concentrations onto the surface of the plate wells as well as pipette tips, all DNA at a 
concentration of less than 10uM was stored in dT dilution buffer (1X TE with 1 uM 
dT(TTTTTT) to occupy binding sites), and all experiments were performed in dT buffer. 
Double stranded constructs were formed by mixing the two sequences, heating at 95C for 
1 min, then cooling to 25C at .1C/min.  
 For fluorescence assays, a master mix was prepared with 100nM double stranded 
fluorescent reporter (fREP) and 11.5uM MgCl2. After multiple optimization experiments, 
each condition was prepared in a separate tube with 100 nM Gate (a double-stranded 
construct of invader with its dock), 300 nM fuel, and varying concentration of the catalyst 
strands. In order to obtain an accurate time course of the reaction, either the gate or the 
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catalyst was not added until directly before fluorescent readings. The master mix was 
simultaneously added to the tubes with a multichannel pipette. 16uL of the total volume 
of each reaction was then added to a plate and read immediately for the presence of 
fluorescein. The positive control consisted of 100nM invader. Negative controls consisted 
of fREP in dT buffer, fREP with 100nM Gate, and fREP with 100nM Gate and 300nM 
fuel.  
 Peroxidase activity was assessed by incubating the DNA and equimolar hemin at 
room temperature for 20 min in a total volume of 20uL before adding 80uL of substrate 
solution for a final concentration of 2mM hydrogen peroxide and 2mM ABTS. The 
extent of reaction was determined visually after fifteen minutes of peroxidase activity, or 
by taking kinetic absorbance readings at 414nM starting immediately after the addition of 
substrate solution.  
RESULTS 
 The goal of this research is to develop an isothermal, colorimetric, protein-
independent assay for a specific DNA sequence, aimed towards tuberculosis diagnostics, 
but adaptable to any target sequence. First, the activity of EAD2 was assessed to 
determine if 5’ or 3’ extensions disrupted peroxidase activity (Figure 17). Then, the 
optimal ratio of quencher to fluorophore was determined. If there is too much quencher 
relative to fluorophore, the invader strand will bind to free quencher strands, reducing 
sensitivity. If there is little quencher, there will be a high level of fluorescence even in the 
absence of a signal, contributing to a high background. The same principle applies to the 
G-quadruplex reporter and its dock. The optimal dock:output ratio and fuel 
concentrations were also experimentally determined (data not shown). Next, the reporter 
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can spontaneously recover peroxidase activity when the output strand bound to the dock 
strand that had been blocking quadruplex folding (Figure 18).  
 Further experiments led to the achievement of visual amplified detection of a 
catalyst strand (Figure 19). In the absence of fuel, each catalyst strand can displace a 
maximum of one output strand, and .25uM of catalyst is not visually observable. In the 
presence of fuel, however, each catalyst strand can release multiple output strands, which 
then increase the effective peroxidase concentration, leading to a clear visual signal of 
.25um catalyst. As G-quadruplex peroxidase activity is sensitive to pH, changing the pH 
of the reaction buffer lowered the limit of detection of both the G-quadruplex and the 
catalyst (Figure 20). With amplification, the fluorescence assay can reliably detect 5nM 
of catalyst in a total volume of 16uL (80 femtomoles) (Figure 21). Furthermore, this 
sensitivity is maintained while disciminating based on as little as a single base-pair 
mutation (Figure 22). While even 25 nM of the wild-type catalyst is able to fully activate 
the fluorescent reporter, 100 nM of the catalyst with a single base-pair mutation does not 
achieve activation above that of the Gate and fuel alone. 
DISCUSSION AND FUTURE DIRECTIONS 
 The goal of this project is to develop a field-ready diagnostic capable of detecting 
a specific target DNA sequence and producing a visual signal. Herein we present the first 
experimental proof that a G-quadruplex can reliably report a signal amplified by strand 
displacement, while discriminating based on a single point mutation. The next step will 
be to adapt the assay to detect a medically relevant sequence, most likely mutated rpoB. 
Future work will focus on increasing the sensitivity of the assay, and setting up the assay 
to work with sputum samples spiked with target nucleic acids, sputum spiked with 
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bacteria, and eventually patient samples. Due to the modular nature of the detection 
scheme, the initial detection module can be changed without having to redesign the rest 
of the test. Therefore, this assay should be able to be easily modified to report the 
presence of any sequence of interest, whether to detect other pathogens, such as HIV, or a 
particular allelic state.  
 Running the assay does not require any special equipment and can be performed 
at room temperature. Both of those characteristics are promising in terms of the 
development of a field test. Further testing will be required to determine how robust the 
system is to temperature and other variables, as “room temperature” can vary widely 
depending on the room. This DNA detection scheme also demonstrates how multiple 
discoveries and advances in basics sciences, such as G-quadruplex peroxidase activity 
and catalytic strand displacement, can be combined to create a medically relevant device, 
in this case a diagnostic assay that is extremely easy to perform and straight-forward to 
interpret.   
V. Conclusion 
 Compared to many other human pathogens, tuberculosis might appear quite tame 
and even boring. Tuberculosis produces no known toxins, unlike botulism, which can 
cause permanent paralysis, or hemorrhagic E. coli, which can rip holes in the digestive 
tract. Unlike Ebola, with a mortality rate approaching 90%
83
, 90% of people infected with 
tuberculosis never even get sick. Tuberculosis replicates extremely slowly. To put the 
growth rate in perspective, if someone started with one bacterium of the nonpathogenic 
E. coli and one M. tuberculosis bacterium, each in their favored medium, after twenty-
four hours, there would be two tuberculosis bacteria and seventeen million E. coli. 
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Finally, unlike Staphylococcus which can instantly gain resistance to many antibiotics 
through the uptake of a plasmid, tuberculosis, which hardly ever uses horizontal gene 
transmission, must slowly accumulate resistance to various antibiotics over time. Despite 
its seemingly unthreatening nature, however, tuberculosis has garnered enormous 
notoriety and attention. 
  With the global increase in population, although rates of TB infection have 
declined, there are more people currently infected with TB than ever before
84
. The rise of 
tuberculosis strains resistant to antibiotics in New York caused an upsurge in new cases 
of tuberculosis in the early 1990’s, after nearly forty years of steady decline. Unless 
proper measures are taken to prevent and contain anti-biotic resistant tuberculosis, 
untreatable strains of tuberculosis will erode the global progress towards the end goal of 
eradicating tuberculosis. The 2010 WHO report on drug resistant tuberculosis reveals that 
the rate of MDR in both new and previously treat tuberculosis cases is increasing in many 
parts of the world, such as Tajikistan, where over 16% of new tuberculosis cases were 
found to be MDR
85
. The emergence of TB strains resistant to antibiotics and the growing 
challenge of TB/HIV coinfection challenge the traditional paradigm of tuberculosis 
having low mortality and progressing slowly. A chilling outbreak of MDR among AIDS 
patients in South Africa killed 52 of 53 patients for a mortality rate of 98% and the 
median time from sputum collection to death was 16 days
86
.  
 Along with the new and continued challenges posed by tuberculosis, new signs of 
promise exist on many fronts. In diagnostics, the QuantiFERON Gold tests have been 
developed to replace tuberculin skin testing, used since the time of Koch. Molecular 
methods and other rapid resistance tests, reduce the time for a clinician to know the 
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susceptibility results for an isolate and be able to treat accordingly. The projects 
presented in this thesis demonstrate the potential of molecular diagnostics in resource 
limited settings, as well as demonstrating the importance of addressing social factors 
when combating tuberculosis. Several new vaccines show promise and are entering 
clinical trials. Continued advances in the basic understanding of tuberculosis can continue 
to drive new approaches to prevent and treat tuberculosis infection. New technologies in 
prevention, diagnostics, and treatment, combined with the technology independent 
strategies of respiratory isolation of infectious individuals, rest and good nutrition to 
bolster the immune system, and basic contact investigation to identify clustered cases of 























Figure 2.  Apparent Cases of Delayed Completion of Therapy for Tuberculosis 


































Figure 3.  Record Errors Discovered Among TB Cases whose DOT Logs and 







































































































































































































































































































































Number Primer Sequence 
1 rpo105 5'-CGT GGA GGC GAT CAC ACC GCA GCAGTT-3' 
2 rpo293 5’- GACCTCCAGCCCGGCACGCTCACG-3’ 


































Figure 15. Mutations Found Among Samples 
 
Mutation by codon Number of samples 
TCG531 TTG  16  
TCG531 TGG  2  
CAC526 CGC  1  
CAC526 AGC  1  
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Figure 16.  DNA Detection via Non-enzymatic Amplification and G-Quadruplex, 














Figure 18. Spontaneous Recovery of G-Quadruplex Peroxidase Activity Upon 
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